Form 4: Bolt Biotherapeutics Director Reprices Stock Options

Bolt Biotherapeutics director Jakob Dupont exchanged existing stock options for new options with lower exercise prices.

Summary

• Jakob Dupont, a director at Bolt Biotherapeutics, engaged in multiple stock option exchanges on December 12, 2025.
• These transactions involved the cancellation of existing 'right to buy' options with higher exercise prices in exchange for new options with lower exercise prices.
• 2,500 options originally priced at $13.596 were exchanged for new options at $5.44. These new options vest 1/36th monthly following September 3, 2024, with full vesting upon a change in control.
• 849 options originally priced at $13.596 were exchanged for new options at $5.44. These new options are fully vested and exercisable.
• 1,000 options originally priced at $7.02 were exchanged for new options at $5.44. These new options are fully vested and exercisable.
• 1,100 options originally priced at $6.4 were exchanged for new options at $5.44. These new options vest on the earlier of May 27, 2026, or the day prior to the next annual meeting of stockholders, with full vesting upon a change in control.
• The total number of options involved in these exchanges was 5,449.

Sentiment

Score: 4

Explanation: The repricing of director stock options, while potentially beneficial for executive retention and motivation, can be viewed negatively by shareholders as it often occurs when the stock price has declined, making original options underwater. This suggests past underperformance relative to the original grant prices.

Positives

• The director received new stock options with significantly lower exercise prices, which could increase their incentive and retention.
• The repricing aligns the director's equity compensation more closely with the current market valuation of the company's stock, potentially re-motivating them.

Negatives

• The exchange of options with higher exercise prices for new options with lower exercise prices suggests that the company's stock price has declined significantly, rendering the original options 'underwater' or out-of-the-money.
• This repricing could be perceived negatively by shareholders as it effectively grants new value to the director without a corresponding increase in shareholder value, potentially leading to dilution if the new options are exercised.

Risks

• Shareholder dissatisfaction and potential governance concerns regarding executive compensation practices, especially if the repricing is not tied to specific performance metrics or if the company's stock has underperformed.
• Perception that management compensation is being adjusted to mitigate personal losses from stock price declines, rather than strictly rewarding future performance.

Future Outlook

New stock options granted to the director have specific vesting schedules, with some vesting monthly following September 3, 2024, and others vesting on the earlier of May 27, 2026, or the day prior to the next annual meeting of stockholders. All options vest in full upon a change in control of the Issuer.

Industry Context

Option repricing is a practice observed in the biotechnology industry, particularly when stock prices experience significant volatility or decline, making existing options underwater. Companies may reprice options to retain and motivate key talent, aligning their incentives with potential future stock appreciation.

Comparison to Industry Standards

• Option repricing is a known practice in the biotech sector, often employed to retain executives when stock prices have fallen significantly, rendering original options out-of-the-money.
• While some companies have strict policies against repricing, others allow it under specific conditions, often requiring board approval and sometimes shareholder approval.
• Governance advocates generally view option repricing with scrutiny, as it can be seen as diluting shareholder value or rewarding executives despite underperformance relative to original grant prices.

Corporate Governance

Related Party Transactions

• The exchange of stock options between Bolt Biotherapeutics and Jakob Dupont, a director, constitutes a related party transaction. This type of transaction is subject to scrutiny to ensure it is conducted on terms fair to the company and its shareholders.

Stakeholder Impact

• Shareholders: Potential negative impact due to perceived dilution, concerns about executive compensation practices, and the implication of past stock underperformance.
• Director (Jakob Dupont): Positive impact through renewed incentive and potential for future gains from lower-priced options.

Next Steps

• Continued vesting of the newly granted stock options for Jakob Dupont based on the specified schedules.

Key Dates

Recommendation

The repricing of director stock options, while a common practice to retain talent when options are underwater, can be a governance concern for shareholders. It suggests that the company's stock price has declined significantly since the original grant dates. While it may incentivize the director, it doesn't inherently signal a strong positive or negative for the company's immediate operational performance, thus a 'hold' recommendation is appropriate pending further financial and operational updates.

Keywords

Bolt Biotherapeutics, BOLT, SEC Form 4, Stock Options, Option Repricing, Director Compensation, Jakob Dupont, Equity Compensation